Chai Discovery

Chai Discovery builds an AI platform for de novo antibody design and molecule discovery for biologics research.

Chai Discovery develops AI models and software for molecular design and drug discovery. Its technology helps scientists predict biochemical structures and interactions and design new proteins, antibodies, and other molecules from target structures or sequences. The platform supports de novo antibody and miniprotein design, helping pharmaceutical and biotechnology research teams evaluate potential drug candidates.

BiOptic

BiOptic software lets AI agents screen drug molecules for potency, safety and deal value, automating pharma asset triage and diligence.

BiOptic runs AI agents that process molecular data, clinical results and economics to rank drug assets. The system checks patents, papers and biotech pipelines to speed up scouting and due diligence. It generates drug candidates and supports licensing and commercialization steps.

Manas AI

Manas AI is a technology company using advanced AI and computational chemistry to accelerate drug discovery for cancer and rare diseases.

Manas AI is a drug discovery company that uses artificial intelligence and computational chemistry to accelerate the development of new medicines. The company combines proprietary AI models, advanced molecular docking techniques, and biological expertise to identify promising drug candidates for cancer and rare diseases. Manas AI’s platform generates custom chemical libraries and employs AI filters to rapidly select high-potential therapeutic compounds. Through a partnership with Microsoft, the company leverages cloud computing to perform molecular docking at speeds 100 times faster than traditional methods. Manas AI is currently focused on developing treatments for aggressive cancers, with plans to expand into other disease areas in the future.

Xeureka

Xeureka is a cutting-edge company that specializes in early drug discovery research using computer technology, including AI and simulations.

Xeureka develops computational drug discovery solutions that combine AI, molecular simulations, and high-performance computing. Its technology supports hit identification, virtual screening, molecular activity prediction, and lead optimization, while its Tokyo-1 platform provides GPU computing and AI resources for pharmaceutical research.

XtalPi

XtalPi, is a biotech firm that uses artificial intelligence and computing to accelerate the development of new drugs.

XtalPi develops AI-powered drug discovery and research platforms that combine artificial intelligence, physics-based modeling, quantum computing, and robotic laboratory automation. Its technology supports molecular design, virtual screening, drug optimization, chemical synthesis, biologics discovery, and solid-state research.

Insilico Medicine

Insilico Medicine is a leading biotechnology company that utilizes artificial AI for every step of pharmaceutical research and development.

Insilico Medicine develops generative AI technology for end-to-end drug discovery and development. Its Pharma.AI platform combines AI-driven target discovery, molecular design, biomarker research, clinical trial analysis, and laboratory automation to advance potential therapies across areas including cancer, fibrosis, immunology, and aging-related diseases.

Healx

Healx leverages the power of Artificial Intelligence (AI) to accelerate the discovery and development of treatments for rare diseases.

Healx is an AI-powered drug discovery company focused on rare diseases. Its platform analyzes biomedical data, scientific literature, and drug information to identify new relationships between diseases and compounds. Healx combines AI predictions with drug discovery expertise and laboratory testing to advance potential treatments through its development pipeline.

Absci

Absci is a pioneering biotechnology company that leverages generative artificial intelligence (AI) for drug creation.

Absci is a generative AI drug creation company combining AI, proprietary biological data, and high-throughput wet-lab validation to design and optimize biologic drugs. Its platform uses generative AI for de novo antibody design, target discovery, and lead optimization, with applications across challenging therapeutic targets.